You are here

Session on G-CSF: prophylaxis of febrile neutropenia

By Matti Aapro, recorded at TAO (Transatlantic Oncology meeting), Nov 20-21, 2014, Paris

3 - Matti Aapro ANG

Febrile neutropenia is associated with considerable morbidity and mortality as well as increased costs. The use of G-CSF for the prevention of febrile neutropenia is a validated approach and G-CSF may also reduce the risk of asthenia, mucositis and diarrhea. Matti Aapro presents the guidelines of the French speaking association for supportive care in cancer (AFSOS) according to which G-CSF prophylaxis is indicated if a patients’ risk of febrile neutropenia is 20% or higher while patients with a risk of 10–20% should be evaluated with regard to their individual risk factors. Prevention is of major importance as it has been shown that comorbid conditions and infectious complications were significantly associated with increased mortality, but adherence to clinical guidelines is poor and patients are generally undertreated with G-CSF. Matti Aapro also reviews the different types of G-CSF and compares long-acting and short-acting G-CSF.

Matti Aapro, Clinique de Genolier, Switzerland

Search this site

Featured videos

Free access to ebooks on cachexia and CINV


Prevention of nausea and vomiting in
adult cancer patients receiving tumour-
directed therapy – 2017 update –

Cancer cachexia: mechanisms and progress in treatment


Stay up-to-date with our monthly e-alert

If you want to regularly receive information on what is happening in Quality of Life in Oncology research sign up to our e-alert.

Subscribe »

QOL (Quality of Life) newsletter e-alert

Quality of Life promotional video

Made possible by an educational grant from Helsinn

Helsinn does not have any influence on the content and all items are subject to independent peer and editorial review

Society Partners

European Cancer Organisation Logo